NLS Total Assets from 2010 to 2024

NLSP Stock

USD 3.66 0.10 2.81%

NLS Pharmaceutics Total Assets yearly trend continues to be relatively stable with very little volatility. Total Assets are likely to grow to about 3.3 M this year. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2010-12-31

Previous Quarter

1.8 M

Current Value

3.3 M

Quarterly Volatility

2.2 M

Credit Downgrade

Yuan Drop

Covid

Check NLS Pharmaceutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NLS Pharmaceutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.8 K, Interest Expense of 137.9 K or Selling General Administrative of 6.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NLS financial statements analysis is a perfect complement when working with NLS Pharmaceutics Valuation or Volatility modules.

Check out the analysis of NLS Pharmaceutics Correlation against competitors.

Latest NLS Pharmaceutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of NLS Pharmaceutics AG over the last few years. Total assets refers to the total amount of NLS Pharmaceutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in NLS Pharmaceutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. NLS Pharmaceutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NLS Pharmaceutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 1.85 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

NLS Total Assets Regression Statistics

	Arithmetic Mean	2,705,540
	Geometric Mean	1,990,120
	Coefficient Of Variation	81.39
	Mean Deviation	1,368,113
	Median	2,288,169
	Standard Deviation	2,202,083
	Sample Variance	4.8T
	Range	9.1M
	R-Value	0.33
	Mean Square Error	4.7T
	R-Squared	0.11
	Significance	0.24
	Slope	160,640
	Total Sum of Squares	67.9T

NLS Total Assets History

	2024	3.3 M
	2023	1.8 M
	2022	9.3 M
	2021	5.8 M
	2020	1.2 M
	2019	696.4 K
	2018	145.6 K

Other Fundumenentals of NLS Pharmaceutics

Intangibles To Total Assets

NLS Pharmaceutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Short Long Term Debt	Capital Stock	Short Term Debt	Current Deferred Revenue	Deferred Long Term Liab	Property Plant Equipment
Total Assets		0.89	0.66	-0.78	-0.46	0.07	-0.33	-0.18	-0.63	0.42	0.99	0.61	0.53	0.46	0.6	0.38	0.51	0.5	-0.02
Total Stockholder Equity	0.89		0.55	-0.82	-0.31	0.06	-0.39	-0.14	-0.73	0.42	0.89	0.63	0.32	0.39	0.47	0.55	0.43	0.44	0.26
Net Tangible Assets	0.66	0.55		-0.82	-0.92	0.56	-0.72	-0.68	-0.67	-0.26	0.66	-0.03	0.92	0.73	0.89	0.43	0.78	0.76	-0.61
Net Debt	-0.78	-0.82	-0.82		0.74	-0.58	0.84	0.52	0.81	0.15	-0.73	-0.1	-0.69	-0.77	-0.75	-0.48	-0.8	-0.8	0.2
Retained Earnings	-0.46	-0.31	-0.92	0.74		-0.79	0.82	0.81	0.5	0.54	-0.44	0.35	-0.98	-0.82	-0.92	-0.17	-0.85	-0.83	0.74
Accounts Payable	0.07	0.06	0.56	-0.58	-0.79		-0.88	-0.66	-0.22	-0.82	0.0	-0.69	0.65	0.85	0.67	0.03	0.83	0.83	-0.49
Long Term Debt	-0.33	-0.39	-0.72	0.84	0.82	-0.88		0.71	0.66	0.66	-0.26	0.46	-0.69	-0.82	-0.67	-0.32	-0.84	-0.83	0.45
Net Receivables	-0.18	-0.14	-0.68	0.52	0.81	-0.66	0.71		0.45	0.57	-0.16	0.45	-0.75	-0.66	-0.68	-0.21	-0.68	-0.66	0.63
Total Liab	-0.63	-0.73	-0.67	0.81	0.5	-0.22	0.66	0.45		0.05	-0.61	-0.18	-0.47	-0.36	-0.39	-0.57	-0.43	-0.39	0.21
Net Invested Capital	0.42	0.42	-0.26	0.15	0.54	-0.82	0.66	0.57	0.05		0.48	0.96	-0.4	-0.49	-0.27	0.12	-0.47	-0.45	0.63
Total Current Assets	0.99	0.89	0.66	-0.73	-0.44	0.0	-0.26	-0.16	-0.61	0.48		0.66	0.52	0.4	0.59	0.38	0.45	0.44	-0.02
Net Working Capital	0.61	0.63	-0.03	-0.1	0.35	-0.69	0.46	0.45	-0.18	0.96	0.66		-0.23	-0.32	-0.08	0.27	-0.29	-0.27	0.57
Common Stock	0.53	0.32	0.92	-0.69	-0.98	0.65	-0.69	-0.75	-0.47	-0.4	0.52	-0.23		0.73	0.92	0.09	0.77	0.74	-0.77
Short Long Term Debt	0.46	0.39	0.73	-0.77	-0.82	0.85	-0.82	-0.66	-0.36	-0.49	0.4	-0.32	0.73		0.78	0.36	1.0	1.0	-0.39
Capital Stock	0.6	0.47	0.89	-0.75	-0.92	0.67	-0.67	-0.68	-0.39	-0.27	0.59	-0.08	0.92	0.78		0.14	0.8	0.81	-0.5
Short Term Debt	0.38	0.55	0.43	-0.48	-0.17	0.03	-0.32	-0.21	-0.57	0.12	0.38	0.27	0.09	0.36	0.14		0.39	0.39	0.1
Current Deferred Revenue	0.51	0.43	0.78	-0.8	-0.85	0.83	-0.84	-0.68	-0.43	-0.47	0.45	-0.29	0.77	1.0	0.8	0.39		1.0	-0.43
Deferred Long Term Liab	0.5	0.44	0.76	-0.8	-0.83	0.83	-0.83	-0.66	-0.39	-0.45	0.44	-0.27	0.74	1.0	0.81	0.39	1.0		-0.38
Property Plant Equipment	-0.02	0.26	-0.61	0.2	0.74	-0.49	0.45	0.63	0.21	0.63	-0.02	0.57	-0.77	-0.39	-0.5	0.1	-0.43	-0.38

Click cells to compare fundamentals

About NLS Pharmaceutics Financial Statements

NLS Pharmaceutics shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although NLS Pharmaceutics investors may analyze each financial statement separately, they are all interrelated. The changes in NLS Pharmaceutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on NLS Pharmaceutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

		Last Reported	Projected for Next Year
	Total Assets	1.8 M	3.3 M

Pair Trading with NLS Pharmaceutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NLS Pharmaceutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NLS Pharmaceutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with NLS Stock

0.8	ME	23Andme Holding	Pair Corr
0.85	VALN	Valneva SE ADR	Pair Corr
0.76	JNJ	Johnson Johnson Sell-off Trend	Pair Corr

Moving against NLS Stock

0.52	MDGL	Madrigal Pharmaceuticals	Pair Corr
0.5	KZR	Kezar Life Sciences	Pair Corr
0.42	NXGLW	NexGel Warrant	Pair Corr
0.4	RNXT	RenovoRx	Pair Corr
0.36	MLYS	Mineralys Therapeutics,	Pair Corr

The ability to find closely correlated positions to NLS Pharmaceutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NLS Pharmaceutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NLS Pharmaceutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NLS Pharmaceutics AG to buy it.

The correlation of NLS Pharmaceutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NLS Pharmaceutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NLS Pharmaceutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for NLS Pharmaceutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for NLS Stock Analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC